GlassScriptPhysician profile
Christine Pasquarella
NPI 1932466745
$2,269.57
in general payments reported to CMS, 2019-2025
14 companies · $637 in 2025
The $637 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $58.23 · 2021: $134 · 2022: $259 · 2023: $679 · 2024: $349 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.62 | 2019-2025 | |
| Qol Medical, LLC | $447.05 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $432.94 | 2020-2025 | |
| Echosens North America, INC. | $429.27 | 2023 | Fibroscan |
| Takeda Pharmaceuticals U.S.A., INC. | $117.49 | 2021-2025 | Eohilia |
| Neuraxis, INC. | $102.11 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $77.08 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $69.32 | 2023-2024 | Linzess |
| Celltrion USA INC. | $28.52 | 2025 | Vegzelma |
| Mirum Pharmaceuticals, INC. | $22.86 | 2024 | Cholbam |
| Amgen INC. | $17.76 | 2023 | Amjevita |
| Pharming Healthcare, INC. | $17.16 | 2023 | Ruconest |
| Alexion Pharmaceuticals, INC. | $16.23 | 2019 | |
| Avanos Medical | $13.16 | 2024 | Endoscopy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Pasquarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.